Press Releases :: Sutro Biopharma, Inc. (STRO)

Apr 1, 2019 5:00 am EDT

Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments

Mar 15, 2019 7:00 am EDT

Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers

Mar 5, 2019 7:00 am EST

Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference

Jan 29, 2019 7:00 am EST

Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry

Jan 3, 2019 4:05 pm EST

Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference

Dec 19, 2018 7:00 am EST

Sutro Achieves $10 Million Milestone Payment from Celgene

Nov 26, 2018 7:00 am EST

Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference

Nov 14, 2018 5:33 pm EST

Sutro Biopharma Reports Third Quarter 2018 Financial Results

Nov 13, 2018 7:00 am EST

Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer

Nov 8, 2018 7:00 am EST

Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors